PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

NCT06762405 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

Interventions

RADIATION: radiotherapy
DRUG: Dostarlimab
BIOLOGICAL: Biological study on circulating tumor DNA (optional for the patient)

Sponsor

Centre Hospitalier Universitaire Dijon